Table 1.

Patient characteristics according to statin use

	Statin-naïve patients (n = 76)	Statin users (n = 22)	p value
Center			0.102
South Korean	30 (39.5)	13 (59.1)
Southern Californian	46 (60.5)	9 (40.9)
Age, years	68.9±14.31	77±7.62	0.031
Female gender	48 (63.2)	13 (59.1)	0.729
Hypertension	43 (56.6)	18 (81.8)	0.032
Diabetes	11 (14.5)	5 (22.7)	0.345
Current smoking	7 (9.2)	4 (18.2)	0.260
Dyslipidemia	7 (9.3)	14 (66.7)	<0.001
Previous stroke	20 (26.3)	5 (22.7)	0.734
Previous coronary heart disease	13 (17.1)	9 (40.9)	0.039
NIH stroke scale	17 [15–20]	19 [14–23]	0.343
Systolic blood pressure, mm Hg	155 [137–176]	160 [145–170]	0.327
Time from onset to TFCA, min	240 [191.5–328.5]	263 [197–396]	0.558
Intravenous t-PA treatment	43 (56.6)	9 (40.9)	0.223
Blood pressure medication
β-Blocker	19 (33.3)	11 (57.9)	0.058
Ca2+ channel blocker	8 (15.4)	3 (15.8)	1.000
ARB/ACE inhibitor	20 (28.6)	9 (42.9)	0.218
Antithrombotic agent			0.190
Antiplatelets	27 (36)	12 (60)	0.072
Warfarin	14 (18.7)	4 (20)	1.000
Aspirin + warfarin	3 (4)	0 (0)	1.000
Laboratory findings, mg/dl
Glucose	123.3±27.78	137.8±46.89	0.441
Triglyceride	90.3±47.82	121.2±47.82	0.004
HDL cholesterol	50.2±18.28	47.0±26.16	0.105
LDL cholesterol	104.3±31.67	77.1±18.16	<0.001
Excellent collateral			0.049
Absence	55 (72.4)	11 (50)
Presence	21 (27.6)	11 (50)

Statistically significant p values are highlighted in italics. Values are represented as means ± SD, numbers with percentages in parentheses or medians with interquartile ranges in square brackets. ARB = Angiotensin II receptor blocker; ACE = angiotensin-converting enzyme; TFCA = transfemoral cerebral angiography; t-PA = tissue-type plasminogen activator; HDL = high-density lipoprotein; LDL = low-density lipoprotein.